Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIOngoingD-0097-2026

Drug recall · October 29, 2025

Opdualag recall

Why: Lack of Assurance of Sterility.

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11

Lots / codes

Lot: 033A23B, Expiry: 4/30/2026

Quantity
12,778 total vials
Company
Bristol-Myers Squibb Company, New Brunswick, NJ
Distribution
Nationwide in the USA
Initiated
October 21, 2025 · Voluntary: Firm initiated
Classified
October 23, 2025
Reported
October 29, 2025
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.